News
DGX
230.97
+0.07%
0.16
Illumina Inc. Stock Rallies 5.1%, Outperforms Peers
Dow Jones · 22h ago
Illumina Inc. stock outperforms competitors on strong trading day
MarketWatch · 22h ago
These healthcare stocks have the highest EPS revision grade ahead of Q3 results
Seeking Alpha · 1d ago
Is Quest Diagnostics (DGX) Undervalued Following New Haystack MRD Study Results?
Simply Wall St · 1d ago
Natera: Priced To Perfection Amidst Rising Competitive Threats
Seeking Alpha · 3d ago
Quest Diagnostics Is Maintained at Overweight by Barclays
Dow Jones · 3d ago
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260
Benzinga · 3d ago
Quest Diagnostics price target raised to $260 from $250 at Barclays
TipRanks · 3d ago
Barclays Keeps Their Buy Rating on Quest Diagnostics (DGX)
TipRanks · 3d ago
Quest Diagnostics announces executive transition and leadership continuity
TipRanks · 3d ago
Illumina Inc. Stock Slides 6.9%, Underperforms Peers
Dow Jones · 3d ago
Ex-Div Reminder for Quest Diagnostics (DGX)
NASDAQ · 5d ago
Weekly Report: what happened at DGX last week (0928-1002)?
Weekly Report · 5d ago
How Investors May Respond To Quest Diagnostics (DGX) Solid Tumor Test Validation
Simply Wall St · 6d ago
The Week That Was, The Week Ahead: Macro and Markets, October 4
TipRanks · 6d ago
Dividend Champion, Contender, And Challenger Highlights: Week October 4
Seeking Alpha · 10/02 22:18
Interested In Quest Diagnostics' (NYSE:DGX) Upcoming US$0.86 Dividend? You Have Three Days Left
Simply Wall St · 10/02 11:20
Apple's Betting Improved Heart and Health Insights Will Boost Watch Sales
Barron‘s · 10/01 16:04
Quest Diagnostics’ Haystack MRD shows efficacy in colorectal cancer detection
TipRanks · 10/01 13:00
Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials
PR Newswire · 10/01 12:52
More
Webull provides a variety of real-time DGX stock news. You can receive the latest news about Quest Diagnostics Inc through multiple platforms. This information may help you make smarter investment decisions.
About DGX
Quest Diagnostics Incorporated is a provider of diagnostic information services. It provides diagnostic insights from the results of its laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and its connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. Its other customers include health plans, employers, emerging retail healthcare providers, government agencies, and others. Its services are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.